Literature DB >> 23573829

IRF8 is associated with germinal center B-cell-like type of diffuse large B-cell lymphoma and exceptionally involved in translocation t(14;16)(q32.33;q24.1).

Marianne Tinguely1, Svenja Thies, Simona Frigerio, Tanja Reineke, Dimitri Korol, Dieter R Zimmermann.   

Abstract

Chromosomal translocations involving the immunoglobulin loci represent frequent oncogenic events in B-cell lymphoma development. Although IRF8 (ICSBP-1) protein expression has been demonstrated in germinal center B-cells and related lymphomas in a single report, the IRF8 gene was not described as an immunoglobulin heavy chain (IGH) translocation partner. In a discovery-driven approach we searched for new translocation partners of IGH in diffuse large B-cell lymphoma (DLBCL) by long distance inverse polymerase chain reaction (LDI-PCR) and Sanger sequencing. A t(14;16)(q32.33;q24.1) IGH/IRF8 was detected in a CD5+de novo DLBCL, confirmed by translocation specific PCR and fluorescence in situ hybridization (FISH) analysis. No further IRF8 aberration could be identified either by LDI-PCR in an additional five CD5+DLBCLs or by FISH on 78 formalin-fixed paraffin-embedded biopsies. Subsequent screening for IRF8 by immunohistochemistry revealed IRF8 expression in 18/78 (23%), correlating with a germinal center B-cell-like (GCB) type of DLBCL. This hitherto unknown translocation t(14;16)(q32.33;q24.1) is likely to represent the initiator of a multistep lymphomagenesis in a CD5+de novo DLBCL.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23573829     DOI: 10.3109/10428194.2013.793324

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  7 in total

1.  Diagnostic Dilemmas in Aggressive Large B Cell Neoplasms with Enigmatic Immunohistochemical Profile: How Far Should We Investigate?

Authors:  Neha Singh; Sunil Pasricha; Narendra Agrawal; Jatin S Gandhi; Ajit Panaych; Anurag Mehta; Rayaz Ahmed; Dinesh Bhurani
Journal:  Indian J Hematol Blood Transfus       Date:  2017-06-15       Impact factor: 0.900

2.  Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1.

Authors:  Joseph D Dekker; Daechan Park; Arthur L Shaffer; Holger Kohlhammer; Wei Deng; Bum-Kyu Lee; Gregory C Ippolito; George Georgiou; Vishwanath R Iyer; Louis M Staudt; Haley O Tucker
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-19       Impact factor: 11.205

3.  Generation and characterization of the Eµ-Irf8 mouse model.

Authors:  Zhijun Qiu; Kenneth N Holder; An-Ping Lin; Jamie Myers; Shoulei Jiang; Karla M Gorena; Marsha C Kinney; Ricardo C T Aguiar
Journal:  Cancer Genet       Date:  2020-06-03

4.  Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.

Authors:  Weijie Zhong; Xin Xu; Zhigang Zhu; Qinghua Du; Hong Du; Li Yang; Yanying Ling; Huabao Xiong; Qingshan Li
Journal:  Oncotarget       Date:  2017-07-25

5.  IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma.

Authors:  Suraya Elfrink; Martin Ter Beest; Luuk Janssen; Marijke P Baltissen; Pascal W T C Jansen; Angelique N Kenyon; Raymond M Steen; Daynelys de Windt; Philipp M Hagemann; Corine Hess; Dick-Johan van Spronsen; Brigiet Hoevenaars; Ellen van der Spek; Zijun Y Xu-Monette; Ken H Young; Charlotte Kaffa; Sander Bervoets; Jolien van Heek; Eva Hesius; Charlotte M de Winde; Michiel Vermeulen; Michiel van den Brand; Blanca Scheijen; Annemiek B van Spriel
Journal:  Blood Adv       Date:  2022-04-12

6.  A global analysis of the complex landscape of isoforms and regulatory networks of p63 in human cells and tissues.

Authors:  Isha Sethi; Rose-Anne Romano; Christian Gluck; Kirsten Smalley; Borivoj Vojtesek; Michael J Buck; Satrajit Sinha
Journal:  BMC Genomics       Date:  2015-08-07       Impact factor: 3.969

7.  Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy.

Authors:  Lucy C Fox; Costas K Yannakou; Georgina Ryland; Stephen Lade; Michael Dickinson; Belinda A Campbell; Henry Miles Prince
Journal:  Int J Mol Sci       Date:  2018-06-13       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.